Navigation Links
Mr. Jean-Pierre Garnier Concludes his Mission at the Pierre Fabre Company
Date:6/28/2010

CASTRES, France, June 28, 2010 /PRNewswire/ -- Mr Jean-Pierre Garnier will step down on September 1st 2010, two years after having been appointed CEO of the Pierre Fabre Group.

"The Company is in excellent health, and is poised to experience a bright future ; I am glad to have contributed to its success and I take this opportunity to thank Mr. Pierre Fabre, visionary founder, for having entrusted me with this important mission".

Mr. Pierre Fabre thanked Mr Jean-Pierre Garnier for his "commitment and the excellent work performed" and stated that "his contribution over the past two years has been of the utmost benefit to the Company".

The new governance, which will continue in the spirit of the current organisation, will be announced in the near future.

    About Pierre Fabre group :

    The Pierre Fabre Group, the second largest independent French
    pharmaceutical company and leader in the field of in-pharmacy
    dermocosmetics, employs about 10,000 people worldwide, including 1,400 R&D
    staff, and generates a turnover of EUR 1.8 billion.

    In 2009, Pierre Fabre Medicament dedicated 28% of its annual turnover to
    R&D in four priority therapeutic areas in public health: oncology, central
    nervous system, dermatology, cardio-vascular/metabolism.

    To learn more about Pierre Fabre, please refer to
    http://www.pierre-fabre.com.

    Press Contact :

    Djamila Hazene-Kedjem
    djamila.hazene.kedjem@pierre-fabre.com
    +33(0)1-49-10-81-72 / +33(6)89-45-87-95



'/>"/>
SOURCE Groupe Pierre Fabre
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
2. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
3. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
4. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
5. Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
6. Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
7. Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
8. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
9. Indevus Announces Submission of New Drug Application
10. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
11. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
(Date:6/23/2016)... June 23, 2016 The Biotechnology ... continues to present great opportunities to investors. Stock-Callers.com assesses ... Intrexon Corp. (NYSE: XON ), Vertex Pharmaceuticals ... (NASDAQ: ARNA ), and Regeneron Pharmaceuticals Inc. ... stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):